Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the first quarter of 2025, showing a slight decrease in revenue but an increase in net profit compared to the previous year. The financial report highlights a net increase in cash and cash equivalents, along with a rise in total assets and owner’s equity, indicating a strong financial position despite the revenue dip. Stakeholders are advised to exercise caution as the financials are unaudited and may be subject to adjustments.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. It holds a significant equity interest in Jiangzhong Pharmaceutical, a company listed on the Shanghai Stock Exchange, which is a key player in the Chinese pharmaceutical market.
YTD Price Performance: -19.26%
Average Trading Volume: 1,550
Technical Sentiment Signal: Buy
Current Market Cap: €3.5B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.